Literature DB >> 23812388

Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism.

Norihito Moniwa1, Jasmina Varagic, Stephen W Simington, Sarfaraz Ahmad, Sayaka Nagata, Jessica L Voncannon, Carlos M Ferrario.   

Abstract

Angiotensin-(1-12) [ANG-(1-12)], a new member of the renin-angiotensin system, is recognized as a renin independent precursor for ANG II. However, the processing of ANG-(1-12) in the circulation in vivo is not fully established. We examined the effect of angiotensin converting enzyme (ACE) and chymase inhibition on angiotensin peptides formation during an intravenous infusion of ANG-(1-12) in normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). WKY and SHR were assigned to a short ANG-(1-12) infusion lasting 5, 15, 30, or 60 min (n = 4-10 each group). In another experiment WKY and SHR were assigned to a continuous 15-min ANG-(1-12) infusion with pretreatment of saline, lisinopril (10 mg/kg), or chymostatin (10 mg/kg) (n = 7-13 each group). Saline or lisinopril were infused intravenously 15 min before the administration of ANG-(1-12) (2 nmol·kg(-1)·min(-1)), whereas chymostatin was given by bolus intraperitoneal injection 30 min before ANG-(1-12). Infusion of ANG-(1-12) increased arterial pressure and plasma ANG-(1-12), ANG I, ANG II, and ANG-(1-7) levels in WKY and SHR. Pretreatment with lisinopril caused increase in ANG-(1-12) and ANG I and large decreases in ANG II compared with the other two groups in both strains. Pretreatment of chymostatin had no effect on ANG-(1-12), ANG I, and ANG II levels in both strains, whereas it increased ANG-(1-7) levels in WKY. We conclude that ACE acts as the primary enzyme for the conversion of ANG-(1-12) to smaller angiotensin peptides in the circulation of WKY and SHR and that chymase may be an ANG-(1-7) degrading enzyme.

Entities:  

Keywords:  angiotensin I; angiotensin II; angiotensin converting enzyme; angiotensin-(1–12); angiotensin-(1–7); blood pressure; chymase; hypertension

Mesh:

Substances:

Year:  2013        PMID: 23812388      PMCID: PMC3761328          DOI: 10.1152/ajpheart.00210.2013

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  38 in total

1.  [Activity of chymotrypsin-like proteinases in patients with ischemic heart disease, arterial hypertension and nonspecific aortic arteritis].

Authors:  G G Arabidze; L A Belova; N M Chikhladze; L S Shapkina; O G Ogorodnikova; V V Kukharchuk
Journal:  Ter Arkh       Date:  2000       Impact factor: 0.467

Review 2.  The renin-angiotensin-aldosterone system: a specific target for hypertension management.

Authors:  M R Weir; V J Dzau
Journal:  Am J Hypertens       Date:  1999-12       Impact factor: 2.689

Review 3.  Multiple mechanisms for the action of chymase inhibitors.

Authors:  Shinji Takai; Denan Jin; Mizuo Miyazaki
Journal:  J Pharmacol Sci       Date:  2012-02-14       Impact factor: 3.337

4.  Calpain inhibitor-1 reduces renal ischemia/reperfusion injury in the rat.

Authors:  P K Chatterjee; P A Brown; S Cuzzocrea; K Zacharowski; K N Stewart; H Mota-Filipe; M C McDonald; C Thiemermann
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

5.  Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.

Authors:  Norihito Moniwa; Jasmina Varagic; Sarfaraz Ahmad; Jessica L VonCannon; Carlos M Ferrario
Journal:  Ther Adv Cardiovasc Dis       Date:  2012-01-05

6.  Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney.

Authors:  Brian M Westwood; Mark C Chappell
Journal:  Peptides       Date:  2012-04-03       Impact factor: 3.750

7.  Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system.

Authors:  Sayaka Nagata; Johji Kato; Kenji Kuwasako; Maki Asami; Kazuo Kitamura
Journal:  Hypertens Res       Date:  2011-10-13       Impact factor: 3.872

8.  Chymase mediates angiotensin-(1-12) metabolism in normal human hearts.

Authors:  Sarfaraz Ahmad; Chih-Chang Wei; Jose Tallaj; Louis J Dell'Italia; Norihito Moniwa; Jasmina Varagic; Carlos M Ferrario
Journal:  J Am Soc Hypertens       Date:  2013-01-10

9.  Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes.

Authors:  Sarfaraz Ahmad; Jasmina Varagic; Brian M Westwood; Mark C Chappell; Carlos M Ferrario
Journal:  PLoS One       Date:  2011-01-10       Impact factor: 3.240

10.  Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss.

Authors:  Chih-Chang Wei; Yuanwen Chen; Lindsay C Powell; Junying Zheng; Ke Shi; Wayne E Bradley; Pamela C Powell; Sarfaraz Ahmad; Carlos M Ferrario; Louis J Dell'Italia
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more
  17 in total

1.  Differential Expression of the Angiotensin-(1-12)/Chymase Axis in Human Atrial Tissue.

Authors:  Hao Wang; Jasmina Varagic; Sayaka Nagata; Neal D Kon; Sarfaraz Ahmad; Jessica L VonCannon; Kendra N Wright; Xuming Sun; Dwight Deal; Leanne Groban; Carlos M Ferrario
Journal:  J Surg Res       Date:  2020-04-30       Impact factor: 2.192

Review 2.  Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate.

Authors:  Sarfaraz Ahmad; Jasmina Varagic; Leanne Groban; Louis J Dell'Italia; Sayaka Nagata; Neal D Kon; Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

3.  Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene.

Authors:  Carlos M Ferrario; Jessica VonCannon; Yan Jiao; Sarfaraz Ahmad; Michael Bader; Louis J Dell'Italia; Leanne Groban; Jasmina Varagic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-02-12       Impact factor: 4.733

Review 4.  Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Jasmina Varagic; Che Ping Cheng; Leanne Groban; Hao Wang; James F Collawn; Louis J Dell Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733

5.  Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue.

Authors:  Sayaka Nagata; Jasmina Varagic; Neal D Kon; Hao Wang; Leanne Groban; Stephen W Simington; Sarfaraz Ahmad; Louis J Dell'Italia; Jessica L VonCannon; Dwight Deal; Carlos M Ferrario
Journal:  Ther Adv Cardiovasc Dis       Date:  2015-06-16

6.  Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody in a humanized model of hypertension.

Authors:  Carlos M Ferrario; Jessica L VonCannon; Jie Zhang; Jorge P Figueroa; Kendra N Wright; Leanne Groban; Amit Saha; J Wayne Meredith; Sarfaraz Ahmad
Journal:  Peptides       Date:  2021-12-18       Impact factor: 3.750

Review 7.  An evolving story of angiotensin-II-forming pathways in rodents and humans.

Authors:  Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia
Journal:  Clin Sci (Lond)       Date:  2014-04       Impact factor: 6.124

8.  Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme.

Authors:  Sarfaraz Ahmad; Jasmina Varagic; Jessica L VonCannon; Leanne Groban; James F Collawn; Louis J Dell'Italia; Carlos M Ferrario
Journal:  Biochem Biophys Res Commun       Date:  2016-07-25       Impact factor: 3.575

9.  Angiotensin (1-12) in Humans With Normal Blood Pressure and Primary Hypertension.

Authors:  Carlos M Ferrario; Seethalakshmi R Iyer; John C Burnett; Sarfaraz Ahmad; Kendra N Wright; Jessica L VonCannon; Amit Saha; Leanne Groban
Journal:  Hypertension       Date:  2021-01-19       Impact factor: 10.190

10.  Reversal of angiotensin-(1-12)-caused positive modulation on left ventricular contractile performance in heart failure: Assessment by pressure-volume analysis.

Authors:  Tiankai Li; Zhi Zhang; Xiaowei Zhang; Zhe Chen; Heng-Jie Cheng; Sarfaraz Ahmad; Carlos M Ferrario; Che Ping Cheng
Journal:  Int J Cardiol       Date:  2019-09-06       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.